Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Eledon Pharmaceuticals, Inc. (ELDN) had Normalized Pre-Tax Income of $-45.58M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-45.62M |
|
-- |
|
-- |
|
$83.25M |
|
$-83.25M |
|
$37.67M |
|
$-45.58M |
|
|
Normalized Pre-Tax Income |
$-45.58M |
$-45.62M |
|
$-45.62M |
|
$-45.62M |
|
$-45.62M |
|
$-83.25M |
|
$-83.25M |
|
81.84M |
|
81.84M |
|
$-0.52 |
|
$-0.52 |
|
| Balance Sheet Financials | |
$135.69M |
|
-- |
|
$33.32M |
|
$169.01M |
|
$18.34M |
|
-- |
|
$13.89M |
|
$32.23M |
|
$81.08M |
|
$136.78M |
|
$136.78M |
|
75.43M |
|
| Cash Flow Statement Financials | |
$-62.34M |
|
$10.79M |
|
$53.81M |
|
$20.55M |
|
$22.81M |
|
$2.26M |
|
$10.45M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.40 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-62.34M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-56.26% |
|
-33.35% |
|
-26.99% |
|
-33.35% |
|
$1.81 |
|
$-0.76 |
|
$-0.76 |
|